ArticleFrontiers in immunology2026
Case Report: Dual response to efgartigimod in myasthenia gravis and comorbid autoimmune disorders: a case series.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coexistence of myasthenia gravis (MG) with other IgG-mediated autoimmune diseases represents a clinically heterogeneous condition, driven by pathogenic autoantibodies. Efgartigimod, a neonatal Fc receptor antagonist, has the ability to clear all IgG subclasses. Here, we report four cases of MG concomitant with IgG-mediated autoimmune diseases, specifically idiopathic inflammatory myopathies (IIM), Isaacs syndrome, autoimmune encephalitis (AE), and IgG4-related disease (IgG4-RD). All of them demonstrated a favorable therapeutic response to efgartigimod, with marked improvement in QMG and MG-ADL scores, along with disease-specific clinical or laboratory manifestations of the overlapping autoimmune conditions. These cases provide preliminary evidence supporting efgartigimod as a promising treatment option for patients with MG complicated by IgG-mediated autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.